ReviewJournal of experimental neuroscience2019
Neurodegeneration, Heterochromatin, and Double-Stranded RNA.
Review in Journal of experimental neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Analysis of Endogenously Expressed Double-Stranded RNAs in Human Cultured Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Single-Cell Transcriptome Patterns of Transposable Elements in Alzheimer's Disease.Molecular neurobiology · 2025Article
- OAS1: A Protective Mechanism for Alzheimer's Disease? An Exploration of Data and Possible Mechanisms.International journal of molecular sciences · 2025Article
- From bench to bedside: translational insights into aging research.Frontiers in aging · 2025Review
- Aberrant protein aggregation in amyotrophic lateral sclerosis.Journal of neurology · 2024Review
- The reverse transcriptase inhibitor 3TC protects against age-related cognitive dysfunction.Aging cell · 2023Article
- Stress granules are shock absorbers that prevent excessive innate immune responses to dsRNA.Molecular cell · 2023Article
- Pathogenic tau-induced transposable element-derived dsRNA drives neuroinflammation.Science advances · 2023Article
- Aging and aging-related diseases: from molecular mechanisms to interventions and treatments.Signal transduction and targeted therapy · 2022Review
- Molecular interactions underlying the phase separation of HP1α: role of phosphorylation, ligand and nucleic acid binding.Nucleic acids research · 2022Article
- Genome-encoded cytoplasmic double-stranded RNAs, found inScience translational medicine · 2021Article
- Machine learning identifies candidates for drug repurposing in Alzheimer's disease.Nature communications · 2021Article
- The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration.Frontiers in aging neuroscience · 2021Review
- Repetitive elements as a transcriptomic marker of aging: Evidence in multiple datasets and models.Aging cell · 2020Article
- Double-stranded RNA and Toll-like receptor activation: a novel mechanism for blood pressure regulation.Clinical science (London, England : 1979) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Changes in chromatin and epigenetic modifications have been associated with aging and aging-associated neurodegenerative diseases, although the causal relationship between these changes and disease-related pathology has been unclear. Recent studies have now made direct connections between neurodegeneration-associated proteins and derepression of repetitive element transcription due to changes in heterochromatin. We suggest that this derepression leads to an increased accumulation of intracellular double-stranded RNA (dsRNA), with an attendant induction of innate immune responses that contribute to the neuroinflammation found in essentially all age-associated neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.